Role of surgical resection for patients with limited disease-small cell lung cancer. 2015

Tomoyoshi Takenaka, and Mitsuhiro Takenoyama, and Eiko Inamasu, and Tsukihisa Yoshida, and Gouji Toyokawa, and Kaname Nosaki, and Fumihiko Hirai, and Masafumi Yamaguchi, and Mototsugu Shimokawa, and Takashi Seto, and Yukito Ichinose
Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan. Electronic address: ttake@surg2.med.kyushu-u.ac.jp.

OBJECTIVE Although chemotherapy and radiotherapy are recommended for patients with limited disease small cell lung cancer (LD-SCLC), several series have reported favorable survival outcomes even in patients with stages II and III disease who underwent surgical resection. The purpose of this study is to compare the outcomes of the use of surgical resection to the other conventional non-surgical treatments in patients with LD-SCLC with respect to each clinical stage. METHODS We retrospectively reviewed 277 patients who received treatment for LD-SCLC and compared the outcomes of the use of surgical resection to the other conventional non-surgical treatments. RESULTS The clinical stage was stage I in 50 cases (18%), stage II in 53 cases (19%) and stage III in 174 cases (63%). Eighty-eight patients received surgical resection and 189 patients were treated with non-surgical treatment. Surgery was performed in 44 patients (88%) with stage I, 27 patients (52%) with stage II and 17 patients (10%) with stage III disease. The five-year survival rates of the patients according to clinical stage were 58% in stage I, 29% in stage II and 18% in stage III. The five-year survival rates of the patients with and without surgical resection according to clinical stage were as follows: 62% and 25% in stage I (p<0.01), 33% and 24% in stage II (p=0.95), 18% and 18% in stage III (p=0.35), respectively. In 44 propensity score-matched pairs with stages II and III disease, including matching for variables such as age, gender and the PS, the five-year survival rates was better in patients with surgical resection than in those without surgery (p=0.04). CONCLUSIONS Surgical resection is effective for the patients with stage I LD-SCLC and some cases of stage II or III disease.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011013 Pneumonectomy The excision of lung tissue including partial or total lung lobectomy. Bronchoscopic Lung Volume Reduction,Endoscopic Lung Volume Reduction,Lung Volume Reduction,Lung Volume Reduction Surgery,Partial Pneumonectomy,Partial Pneumonectomies,Pneumonectomies,Pneumonectomy, Partial,Reduction, Lung Volume,Volume Reduction, Lung
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Tomoyoshi Takenaka, and Mitsuhiro Takenoyama, and Eiko Inamasu, and Tsukihisa Yoshida, and Gouji Toyokawa, and Kaname Nosaki, and Fumihiko Hirai, and Masafumi Yamaguchi, and Mototsugu Shimokawa, and Takashi Seto, and Yukito Ichinose
September 1995, Chinese medical journal,
Tomoyoshi Takenaka, and Mitsuhiro Takenoyama, and Eiko Inamasu, and Tsukihisa Yoshida, and Gouji Toyokawa, and Kaname Nosaki, and Fumihiko Hirai, and Masafumi Yamaguchi, and Mototsugu Shimokawa, and Takashi Seto, and Yukito Ichinose
July 2003, Thorax,
Tomoyoshi Takenaka, and Mitsuhiro Takenoyama, and Eiko Inamasu, and Tsukihisa Yoshida, and Gouji Toyokawa, and Kaname Nosaki, and Fumihiko Hirai, and Masafumi Yamaguchi, and Mototsugu Shimokawa, and Takashi Seto, and Yukito Ichinose
June 1994, Thorax,
Tomoyoshi Takenaka, and Mitsuhiro Takenoyama, and Eiko Inamasu, and Tsukihisa Yoshida, and Gouji Toyokawa, and Kaname Nosaki, and Fumihiko Hirai, and Masafumi Yamaguchi, and Mototsugu Shimokawa, and Takashi Seto, and Yukito Ichinose
November 2014, Thoracic surgery clinics,
Tomoyoshi Takenaka, and Mitsuhiro Takenoyama, and Eiko Inamasu, and Tsukihisa Yoshida, and Gouji Toyokawa, and Kaname Nosaki, and Fumihiko Hirai, and Masafumi Yamaguchi, and Mototsugu Shimokawa, and Takashi Seto, and Yukito Ichinose
December 2005, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia,
Tomoyoshi Takenaka, and Mitsuhiro Takenoyama, and Eiko Inamasu, and Tsukihisa Yoshida, and Gouji Toyokawa, and Kaname Nosaki, and Fumihiko Hirai, and Masafumi Yamaguchi, and Mototsugu Shimokawa, and Takashi Seto, and Yukito Ichinose
January 2023, Clinical lung cancer,
Tomoyoshi Takenaka, and Mitsuhiro Takenoyama, and Eiko Inamasu, and Tsukihisa Yoshida, and Gouji Toyokawa, and Kaname Nosaki, and Fumihiko Hirai, and Masafumi Yamaguchi, and Mototsugu Shimokawa, and Takashi Seto, and Yukito Ichinose
March 2021, The Journal of thoracic and cardiovascular surgery,
Tomoyoshi Takenaka, and Mitsuhiro Takenoyama, and Eiko Inamasu, and Tsukihisa Yoshida, and Gouji Toyokawa, and Kaname Nosaki, and Fumihiko Hirai, and Masafumi Yamaguchi, and Mototsugu Shimokawa, and Takashi Seto, and Yukito Ichinose
January 2003, Seminars in surgical oncology,
Tomoyoshi Takenaka, and Mitsuhiro Takenoyama, and Eiko Inamasu, and Tsukihisa Yoshida, and Gouji Toyokawa, and Kaname Nosaki, and Fumihiko Hirai, and Masafumi Yamaguchi, and Mototsugu Shimokawa, and Takashi Seto, and Yukito Ichinose
November 1999, Nihon Geka Gakkai zasshi,
Tomoyoshi Takenaka, and Mitsuhiro Takenoyama, and Eiko Inamasu, and Tsukihisa Yoshida, and Gouji Toyokawa, and Kaname Nosaki, and Fumihiko Hirai, and Masafumi Yamaguchi, and Mototsugu Shimokawa, and Takashi Seto, and Yukito Ichinose
January 2001, Pneumonologia i alergologia polska,
Copied contents to your clipboard!